Correlation of Cerebral and Subcutaneous Glycerol in Severe Traumatic Brain Injury and Association with Tissue Damage

Linda Hägglund1, Magnus Olivecrona2 and Lars‑Owe D. Koskinen1*

© 2021 The Author(s)

Abstract

Background: This study is a substudy of a prospective consecutive double-blinded randomized study on the effect of prostacyclin in severe traumatic brain injury (sTBI). The aims of the present study were to investigate whether there was a correlation between brain and subcutaneous glycerol levels and whether the ratio of interstitial glycerol in the brain and subcutaneous tissue (glycerolbrain/sc) was associated with tissue damage in the brain, measured by using the Rotterdam score, S-100B, neuron-specific enolase (NSE), the Injury Severity Score (ISS), the Acute Physiology and Chronic Health Evaluation Score (APACHE II), and trauma type. A potential association with clinical outcome was explored.

Methods: Patients with sTBI aged 15–70 years presenting with a Glasgow Coma Scale Score ≤8 were included. Brain and subcutaneous adipose tissue glycerol levels were measured through microdialysis in 48 patients, of whom 42 had complete data for analysis. Brain tissue damage was also evaluated by using the Rotterdam classification of brain computed tomography scans and the biochemical biomarkers S-100B and NSE.

Results: In 60% of the patients, a positive relationship in glycerolbrain/sc was observed. Patients with a positive correlation of glycerolbrain/sc had slightly higher brain glycerol levels compared with the group with a negative correlation. There was no significant association between the computed tomography Rotterdam score and glycerolbrain/sc. S-100B and NSE were associated with the profile of glycerolbrain/sc. Our results cannot be explained by the general severity of the trauma as measured by using the Injury Severity Score or Acute Physiology and Chronic Health Evaluation Score.

Conclusions: We have shown that peripheral glycerol may flux into the brain. This effect is associated with worse brain tissue damage. This flux complicates the interpretation of brain interstitial glycerol levels. We remind the clinicians that a damaged blood–brain barrier, as seen in sTBI, may alter the concentrations of various substances, including glycerol in the brain. Awareness of this is important in the interpretation of the data bedside as well in research.

Keywords: Traumatic brain injury, Glycerol, S-100B, Neuron-specific enolase, Microdialysis, Brain computed tomography, Outcome

Introduction

Traumatic brain injury (TBI) can be described as mild, moderate, or severe (sTBI) and is often classified on the basis of level of consciousness and/or the length of post-traumatic amnesia. sTBI is the main cause of morbidity and mortality among young adults younger than 40 years of age, and the mortality rate is estimated to be 10 per 100,000 inhabitants per year in Sweden [1]. The overall levels of in-patient care of TBI have seemed to decrease, but there is an increase in older adults [2]. A similar trend is reported in other European countries [3]. In a recent
review, the global burden, consequences, and health economy costs were found to be very large [4].

Glycerol is a molecular component of triglycerides stored in the human fatty tissue. Triglycerides are decomposed into free glycerol and fatty acids through sympathetic activity. Glycerol does not normally pass the blood–brain barrier (BBB). In the central nervous system, glycerol is only present as phospholipid in cell membranes. Therefore, glycerol quantified intracerebrally is used as a measure of brain cell damage and death [5]. This damage may be caused, for example, by direct mechanical damage and metabolic distress, including inflammation. Because the BBB may be damaged by the injury, it is important to reduce further damage to the BBB and to avoid treatment measures that may worsen the leakage through the BBB [6, 7]. In case of a disrupted BBB, there may be an increased transfer into the brain of blood-borne glycerol released from extracranial sources, such as adipose tissue. There is some evidence that peripheral glycerol may penetrate into the central nervous system after brain injury [8]. If this occurs, the value of glycerol as a marker of cerebral tissue injury could be questioned.

Osmotherapy is one of the most commonly used emergency treatment measures in patients with sTBI with high intracranial pressure (ICP). Intraarterial administration of mannitol may open the BBB [9]. Whether this is true for intravenous administration of mannitol, in doses used in the clinical management, leading to influx of peripheral constituents in the brain, is not clear. If osmotherapy would further open an already damaged BBB, allowing blood constituents to penetrate the brain, measurement of, for example, brain extracellular glycerol, would be hard to use as a marker of brain damage. Surprisingly, there are almost no publications reporting on any correlation between cerebral and other sources of glycerol measured temporally.

Brain tissue damage can be quantified on the basis of levels of protein S-100B and neuron-specific enzyme found in the peripheral blood. S-100B is a calcium-binding protein that is mainly found in the glial cells in the central and peripheral nervous system. Measured in blood, it has an estimated sensitivity of 96% and a specificity of 31% to detect intracranial injuries seen on computed tomography (CT) scans [10]. NSE is a glycolytic enzyme found in the cytoplasm of neurons but also in erythrocytes and platelets. It has shown a varying ability to detect brain injuries seen on CT scans [10, 11].

Increased ICP has been shown to be a prognostic factor for poor outcome after TBI [12]. At the university hospital in Umeå, a modified Lund concept is used in the treatment of TBI. The guidelines used in the Lund concept are focused on volume regulation of the brain and microcirculation and aim at controlling ICP and optimizing microcirculation in the penumbra zone. The goal is to reduce or prevent secondary injury, such as ischemia and edema [13, 14].

We hypothesized that cerebral glycerol (glycerolbrain) levels would not be associated with peripheral subcutaneous adipose glycerol (glycerolsc) levels. If a correlation was observed, this might call into question the use of brain glycerol as a solid marker of brain tissue damage not mirrored in the brain CT classification, biochemical biomarkers, and clinical outcome. The first aim was to study the relationship between intra- and extracerebral glycerol (glycerolbrain/sc) levels. The second aim was to study any associations between glycerolbrain/sc and measurements of brain tissue damage, overall injury level, injury type, and clinical outcome.

Methods

Patients

Data were collected from a prospective randomized double-blinded study of prostacyclin versus a placebo [15]. The inclusion criteria were verified severe traumatic head injury, a Glasgow Coma Scale Score (GCS) of 8 or less at intubation and sedation, age between 15 and 70 years, a first measured cerebral perfusion pressure (CPP) of 10 mm Hg or higher, and arrival at our unit within 24 h of trauma. Exclusion criteria were pregnancy or women who were breastfeeding, known bleeding disorder, known allergy to epoprostenol, and penetrating head injury. If the need for intensive care and intubation lasted for less than 72 h in patients discharged from the intensive care unit alive, the injury was considered too mild to be characterized as sTBI, even if the patient initially has a GCS ≤ 8. These patients were excluded. All patients were treated in accordance with the modified Lund concept [13, 15].

In the primary study, 48 patients were included [15]. In this retrospective analysis of prospectively collected data, six patients were excluded because of lack of data regarding concomitant glycerol levels in the brain and subcutaneous tissue (see Fig. 1). Thus, 42 patients were included. Demographics and basic information are given in Table 1.

Monitoring

In all patients, an intraparenchymal ICP-measuring device (Codman MicroSensor, Johnson & Johnson Professional, Raynham, MA) was inserted through a burr hole, approximately at Kocher’s point, preferably on the right side. ICP was measured continuously. Invasive arterial blood pressure was monitored continuously, and the reference level was set at heart level. Mean arterial blood pressure (MAP) and CPP were calculated automatically.
by the monitoring equipment (Marquette Solar, General Electric Medical Systems, Milwaukee, WI) by using the systolic and diastolic blood pressures registered. The reference point for ICP and MAP was at the same level, resulting in an insignificant hydrostatic difference between the measuring sites. No correction for the CPP calculations was therefore needed.

**S-100B and NSE**

Blood samples for biomarkers S100-B and NSE were collected at arrival, and thereafter sampling was repeated at 12-h intervals during the first five days. Centrifugation and freezing of serum in a −70 °C storing freezer was performed immediately after sampling. Analyses were performed with the automatized LIAISON system by using the LIAISON Sangtec 100 assay for analyses of S-100B and the LIAISON NSE assay for the analysis of NSE (AB DiaSorin, Sangtec Medical, Bromma, Sweden). The highest (maximum) levels of S-100B and NSE, as well as the bulk release during the first 72 h, were used in the calculations because we have previously shown that this provides higher sensitivity in describing the injury [16].

**Microdialysis**

Two microdialysis catheters (CMA 70, CMA Microdialysis, Solna, Sweden) with gold tips were placed intracerebrally on each side frontally, approximately at Kocher’s point. Catheter A corresponded to the

---

**Table 1** Demographics and general parameters in relation to brain/subcutaneous glycerol groups

| Age (years) | Sex | GCS, median | ICP (mm Hg), mean ± SD | MAP (mm Hg), mean ± SD | CPP (mm Hg), mean ± SD | Rotterdam-init, median (range) | Catheter tip distance to lesion (mm), mean ± SD |
|------------|-----|-------------|------------------------|------------------------|------------------------|-----------------------------|----------------------------------|
| Total (N=42) | | 37.4 ± 15.2 | 6 (3–8) | 6 (3) | 15.5 ± 12.3 |
| Positive correlation (n=25) | Women=10, men=15 | 34.2 ± 14.8 | 6 (3–7) | 6 (3–7) | 19.1 ± 14.8 |
| Negative correlation (n=17) | Women=5, men=12 | 41.4 ± 15.2 | 6 (3–7) | 6 (3–7) | 15.8 ± 12.3 |

**Fig. 1** A schematic presentation of the inclusion and exclusion of the patients. CPP cerebral perfusion pressure, GCS Glasgow Coma Scale Score
most injured hemisphere, close to the penumbra zone, assessed through the initial CT scan. Catheter B corresponded to the other hemisphere. Another microdialysis catheter, Catheter C (CMA 60, CMA Microdialysis, Solna, Sweden) was placed in the subcutaneous adipose tissue on the upper part of the abdomen.

The flow rate in all three catheters was 0.3 mL/minute, and the CMA 106 and CMA 107 microdialysis pumps (CMA Microdialysis, Solna, Sweden) were used. For the brain catheters, perfusion fluid CNS (CMA Microdialysis, Solna, Sweden) was used, and perfusion fluid T1 (CMA Microdialysis, Solna, Sweden) was used, and perfusion fluid T1 (CMA Microdialysis, Solna, Sweden) was used for the subcutaneous catheter.

The first dialysate was discharged to avoid falsely elevated levels of glycerol due to the minor lesion that could be introduced by the less than 1 mm in diameter microdialysis catheter. Sampling was started 0.5–2.5 h after microdialysis was initiated. Samples were collected for 2 h each over the course of 96 h, resulting in approximately 48 samples per patient. The samples were analyzed by using a CMA 600 analyzer (CMA Microdialysis, Solna, Sweden). If not immediately analyzed, the vials were stored in a freezer (−18 °C) for a maximum of 24 h and thereafter frozen to −70 °C. The microdialysis data were transferred from the CMA 600 analyzer to a computer and further processed with LABpilot software (CMA Microdialysis, Solna, Sweden).

In this publication, we report on the absolute glycerol levels from the catheter in the most injured hemisphere (glycerol_{brain}) and subcutaneous adipose tissue (glycerol_{sc}). For comparison, we also report the glucose (glucose_{brain}), lactate (lactate_{brain}) levels, and the lactate/pyruvate ratio in the brain measured in the same samples as glycerol. The distance from the microdialysis catheter tip to the lesion (hematoma, evacuated hematoma, or contusion) in the brain was calculated from CT scans. In case of diffuse injury, without evacuated hematomas or contusions, the catheter tip was in the edematous tissue and therefore not included in the calculated distance.

The patients were dichotomized into having a positive or negative correlation between cerebral and subcutaneous adipose tissue glycerol levels. A positive correlation was defined as a linear regression plot with a positive slope; a negative correlation, if the slope was negative.

CT Scan Evaluation
The first CT scan of the brain and the scan 24 h after the injury were classified on the basis of the Rotterdam scoring system [10, 17]. The Rotterdam scoring system is used to evaluate CT scans of a damaged brain and to estimate prognosis after TBI. Scores are given on the basis of certain criteria, such as compression of basal cisterns, midline shift, traumatic subarachnoid hemorrhage, intraventricular hemorrhage, and epidural hematoma [18].

Injury Severity and Type of Injury
The Injury Severity Score (ISS) was used for evaluation of the overall injury severity, and the Acute Physiology and Chronic Health Evaluation Score II (APACHE II) was used for measurement of the severity of illness. Type of injury was reported as fall, sports, traffic accident, or assault.

Outcome
The outcome 6 months post injury was evaluated by an independent staff member using structured interviews and the Glasgow Outcome Score Extended (GOSE) scale. The GOSE is a scale ranging from 1 to 8 points, corresponding to a range of outcomes from dead (1 point) to full recovery (8 points) [19].

Statistics
Continuous variables are reported as mean ± standard deviation, and median (range) is given for discrete variables. Statistical analysis was performed by using the software JMP 14.2.0 (SAS Institute, Inc., Cary, NC). The χ^2 test was used for evaluation of differences between proportions. The two-tailed unpaired t-test was used for comparisons of differences between groups with continuous variables. Wilcoxon’s rank-sum test was used for discrete variables and for comparison of S-100B and NSE in relation to glycerol because the S-100B and NSE levels varied. Correlation analysis was performed with Pearson’s linear method or Spearman’s ρ.

Ethics and Approval
The Regional Board of Ethics at Umeå University (00–175) and the Swedish Medical Products Agency (151:633/01) approved the study. The study is registered as a clinical trial (ClinicalTrials.gov identifier NCT01363583).

Results
Demographics and general data are shown in Table 1. All patients had sTBI and a GCS ≤ 8 and were intubated and in need of neurointensive care. The distances from microdialysis catheter tip to lesion are presented in Table 1. Types of accidents were traffic accidents, falls, sports, and assaults (see Table 2). No significant difference between the groups was observed.

There were 25 individuals with a positive glycerol_{brain/sc} correlation (individual Pearson’s R^2 coefficients between
0.0002 and 0.4144) and 17 with a negative correlation (individual Pearson’s R^2 coefficients between 0.000001 and 0.4610). The corresponding regression plot results were significantly different (Table 3). Figure 2 summarises these results. Prostacyclin had no significant effect on the association of glycerol_{brain/sc} in either group (t-test). The mean value of glycerol_{brain} in the first 96 h was slightly higher in the group with a positive correlation of glycerol_{brain/sc} compared with the group with a negative correlation (Table 3). These results are summarised in Fig. 3. There was no significant difference in glycerol_{sc} levels between groups with positive or negative correlation of glycerol_{brain/sc}.

There was no significant difference in mean age (t-test) or GCS (Wilcoxon’s rank-sum test) in the two groups (see Table 1).

No significant association between initial CT Rotterdam score or that after 24 h and glycerol_{brain/sc} (Wilcoxon’s rank-sum test) (Table 1) was observed. There was a positive correlation between the Rotterdam score at 24 h after injury (but not the initial score) and mean glycerol levels in the brain (ρ = 0.3565, p = 0.0221, Spearman). No such correlation was observed with the peripheral glycerol levels. There was a significant association of S-100B_{max}, S-100B_{AUC}, NSE_{max}, and glycerol_{brain/sc} (Wilcoxon’s rank-sum test) (Table 3). We found no association between other brain metabolic markers (glucose, lactate, lactate/pyruvate) and the glycerol_{brain/sc} patterns (Table 3).

MAP (mean 96 h) did not differ between the two groups. No association between ICP or CPP levels (mean 96 h) and glycerol correlation was observed (Table 1).

There was no difference in the proportion of decompressive hemicraniectomies between the groups (χ² test).

Type of injury, ISS, and APACHE II had no impact on the results, and there were no significant differences in these parameters between the groups (Table 1), nor was there any correlation between the brain and peripheral

### Table 2 Types of accidents in relation to brain/subcutaneous glycerol groups

| Injury type   | Total (N = 42) | Positive correlation (n = 25) | Negative correlation (n = 17) |
|---------------|---------------|-------------------------------|-------------------------------|
| Traffic accident | 28 (66.7) | 19 (76) | 9 (52.9) |
| Fall          | 10 (23.8) | 4 (16) | 6 (35.3) |
| Sport         | 1 (2.4)  | 1 (5)  | 0        |
| Assaults      | 3 (7.1)   | 1 (5)  | 2 (11.8) |

Types of accidents in the total material and divided into those with a positive or negative correlation between cerebral and subcutaneous adipose glycerol levels.

### Table 3 Biomarkers in relation to brain/subcutaneous glycerol groups

| Glucose_{brain}, mmol/L | Glycerol_{brain}, mmol/L | Glycerol_{sc}, mmol/L | Lactate/pyruvate, mmol/L | Lactate_{sc}, mmol/L | glucose_{brain}, mean ± SD | Glycerol_{brain}, mean ± SD | Glycerol_{sc}, mean ± SD | Lactate/pyruvate, mean ± SD | Lactate_{sc}, mean ± SD | glucose_{brain}, slope of regression line | Glycerol_{brain}, slope of regression line | Glycerol_{sc}, slope of regression line | Lactate/pyruvate, slope of regression line | Lactate_{sc}, slope of correlation
|-------------------------|--------------------------|-----------------------|--------------------------|----------------------|---------------------------|---------------------------|--------------------------|---------------------------|--------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|
| 7.34 ± 9.58            | 7.15 ± 6.50              | 7.04 ± 7.63           | 1.67 ± 3.3               | 0.82 ± 1.7           | 0.94 ± 1.5                | 0.039 ± 0.018             | 0.0054 ± 0.0020           | 0.0039 ± 0.0018            | 0.0045 ± 0.0017            | 0.0002 ± 0.0001              | 0.0014 ± 0.0008              | 0.0002 ± 0.0001              | 0.0014 ± 0.0008              | 0.0002 ± 0.0001              |
| 7.34 ± 9.58            | 7.15 ± 6.50              | 7.04 ± 7.63           | 1.67 ± 3.3               | 0.82 ± 1.7           | 0.94 ± 1.5                | 0.039 ± 0.018             | 0.0054 ± 0.0020           | 0.0039 ± 0.0018            | 0.0045 ± 0.0017            | 0.0002 ± 0.0001              | 0.0014 ± 0.0008              | 0.0002 ± 0.0001              | 0.0014 ± 0.0008              | 0.0002 ± 0.0001              |
| 7.34 ± 9.58            | 7.15 ± 6.50              | 7.04 ± 7.63           | 1.67 ± 3.3               | 0.82 ± 1.7           | 0.94 ± 1.5                | 0.039 ± 0.018             | 0.0054 ± 0.0020           | 0.0039 ± 0.0018            | 0.0045 ± 0.0017            | 0.0002 ± 0.0001              | 0.0014 ± 0.0008              | 0.0002 ± 0.0001              | 0.0014 ± 0.0008              | 0.0002 ± 0.0001              |
| 7.34 ± 9.58            | 7.15 ± 6.50              | 7.04 ± 7.63           | 1.67 ± 3.3               | 0.82 ± 1.7           | 0.94 ± 1.5                | 0.039 ± 0.018             | 0.0054 ± 0.0020           | 0.0039 ± 0.0018            | 0.0045 ± 0.0017            | 0.0002 ± 0.0001  | 0.0014 ± 0.0008  | 0.0002 ± 0.0001  | 0.0014 ± 0.0008  | 0.0002 ± 0.0001  |

Types of accidents in the total material and divided into those with a positive or negative correlation between cerebral and subcutaneous adipose glycerol levels.
glycerol levels or between the ratio of brain to peripheral glycerol and ISS and APACHE II.

At the 6-month follow-up, the median GOSE was 4 (1–8) in the group with a negative glycerol\textsubscript{brain/sc} correlation and 5 (1–7) in the group with a positive correlation (ns), Wilcoxon's rank-sum test).

**Discussion**

We have shown that in 60% of patients with sTBI, peripheral glycerol may flux into the brain. This effect is associated with worse brain tissue damage, as measured by S-100B and NSE.

Glycerol has been considered as a marker for brain cell damage after TBI \cite{5} and may be correlated with clinical outcome. This damage may be a direct mechanical damage or damage due to metabolic distress. In a situation with a flow of glycerol from the blood into the brain due to, for example, a BBB disruption, the intracerebral glycerol level ceases to mirror the intracerebral condition. In such a situation the glycerol levels in the brain may be misinterpreted to indicate an increased breakdown of brain tissue. In 60% of the patients, a positive correlation was observed. This may be interpreted as there being a possibility of an inflow of glycerol to the brain and may be due to, for example, some kind of BBB dysfunction. Therefore, one might suggest that some caution should be used in interpreting brain interstitial levels of glycerol as a marker of brain cell damage. The pathophysiological mechanism behind the negative correlation between extra- and intracerebral glycerol levels is interesting. One reason for this pattern could be that the peripheral glycerol level mirrors extracranial injuries, resulting in an altered glycerol ratio between peripheral and intracranial tissue. However, we could not identify any difference in type of accident, extracranial injuries, or level of injury severity, as measured by using ISS and APACHE II, nor was there a difference in peripheral glycerol levels between the groups. In addition, we found no indication of a difference in the metabolic patterns in the brain, as reflected in the interstitial concentrations of glucose, lactate, and lactate/pyruvate.

All patients in this study were treated with β-blockers (metoprolol) and α\textsubscript{2}-stimulation (clonidine) to decrease the sympathetic nervous system drive, thus decreasing
the general stress level and by extension, the inflammation process. Because subcutaneous glycerol release is promoted by an activation of the sympathetic nervous system, and we were actively trying to decrease this response, it is unlikely that the general stress levels of the patients influenced the results. We did not measure the blood level of glycerol, but it has previously been reported that subcutaneous glycerol levels measured by microdialysis follows the pattern of glycerol in the blood [20].

There was no significant association of ICP or CPP and glycerolbrain/sc. This can simply reflect effects of the treatment striving to normalize the ICP and CPP. It is more remarkable that the tissue damage categorized by using the Rotterdam score was not associated with extra- to intracranial glycerol correlations. However, surrogate measures of brain tissue damage, i.e., S-100B and NSE, showed more impairment in the patients with a positive correlation of glycerolbrain/sc. This may indicate that the greater the brain tissue damage, the greater the leakage of glycerol from extracerebral tissues (subcutaneous fat) into the brain, which may be due to a disrupted BBB.

We have previously shown that prostacyclin treatment is associated with a stabilization of the pressure reactivity of cerebral vessels [21] and the relation between cerebral glycerol and pressure reactivity in sTBI [22]. Interestingly, in the present study, prostacyclin had no clear-cut influence on the intra- to extracerebral glycerol correlation. Thus, one could speculate, that the previously reported effect of prostacyclin on pressure reactivity and glycerol is not influenced by an extra- to intracerebral glycerol flux.

Some support for our findings may be found in the publication by Meyer et al. [8]. They showed, in patients with cerebral infarction, that intravenous infusion of glycerol entered the brain and cerebrospinal fluid. In addition, glycerol given for treatment of high ICP in patients with brain edema after a large middle cerebral artery infarction resulted in a marked accumulation of brain interstitial glycerol, as measured through microdialysis [23]. To the best of our knowledge, no previous studies have been reported on de novo intra- to extracranial glycerol correlation in sTBI. Thus, it is impossible to compare our results with others. Because glycerol is clinically used as
a very potent hyperosmotic drug in patients with life-threatening intracerebral processes, it is wise to consider that a disrupted BBB may cause leakage of glycerol into the brain tissue. One could speculate that hyperosmotic agents clinically used in attempts to reduce brain edema in patients with sTBI may further increase such leakage, leading to an increased osmotic tissue pressure. This may result in an aggravated tissue edema, a phenomenon that can be observed in these severely ill patients.

As with all clinical and experimental studies, there are strengths and weaknesses. The strengths of our study are that all patients had been treated and monitored in accordance with a predefined schedule. All patients were from a specified region and had sTBI. Weaknesses include that we only studied patients with sTBI and therefore our results cannot directly be applied on patients with mild and moderate head injury. In addition, whether our results are applicable on patients treated by different treatment algorithms is unknown. Our study is too small to draw any certain conclusions. Therefore, further studies must validate or reject the present results.

Conclusions
There may be an influx of glycerol from extracellular sources into the brain, confusing the interpretation of the cerebral glycerol levels. This eventual influx was paralleled with higher S-100B and NSE levels, indicating a worse brain tissue injury. We remind the clinicians and researchers that a damaged BBB, as seen in sTBI, may alter the levels of various substances, including glycerol in the brain. Awareness of this is important in the interpretation of the bedside data as well as in research.

Author details
1. Department of Clinical Science, Neurosciences, Umeå University, Umeå, Sweden. 2. Department of Anesthesia and Intensive Care, Section of Neurosurgery, Örebro University Hospital and Department for Medical Sciences, Faculty of Health and Medicine, Örebro University, Örebro, Sweden.

Author contributions
LH contributed to the study conception, data curation, analysis, and manuscript preparation. MOL and LOOK collected the initial data and contributed to the study conception, analysis of the data, critical review of the manuscript, and final preparation of the manuscript.

Source of support
Open access funding provided by Umeå University. This study was financially supported by the Umeå Clinical Neuroscience Research Fund; Umeå University; a regional agreement between Umeå University and Västerbotten County Council on cooperation in the field of medicine, odontology, and health; the Tore Nilsson Fund; the Kempe Fund; the Capio Research Fund; and Umeå University.

Declarations
Conflict of interest
The authors declare no conflict of interest.

Ethical approval/informed consent
The study adheres to ethical standards and is in accordance with the 1964 Helsinki Declaration. The Regional Board of Ethics at Umeå University (00–175) and the Swedish Medical Products Agency (151:633/01) approved the study. An informed consent procedure was applied.

Open Access
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 26 February 2021 Accepted: 23 November 2021
Published: 16 December 2021

References
1. Sundstrom T, Sollid S, Wentzel-Larsen T, Wester K. Head injury mortality in the Nordic countries. J Neurotrauma. 2007;24(1):147–53.
2. Pedersen K, Fahlstedt M, Jacobsson A, Kleiven S, von Holst H. A National survey of traumatic brain injuries admitted to hospitals in Sweden from 1987 to 2010. Neuroepidemiology. 2015;45(1):20–7.
3. Steyerberg EW, Wiegens E, Sewalt C, et al. Case-mix, care pathways, and outcomes in patients with traumatic brain injury in CENTER-TBI: a European prospective, multicentre, longitudinal, cohort study. Lancet Neurol. 2019;18(10):923–34.
4. Maas AIR, Menon DK, Adelson PD, et al. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. Lancet Neurol. 2017;16(1):987–1048.
5. Merenda A, Gugliotta M, Holloway R, et al. Validation of brain extracellular glycerol as an indicator of cellular membrane damage due to free radical activity after traumatic brain injury. J Neurotrauma. 2008;25(5):527–37.
6. Jungner M, Siemund R, Venturioli D, et al. Blood-brain barrier permeability following traumatic brain injury. Minerva Anestesiol. 2016;82(5):525–33.
7. Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-brain barrier: from physiology to disease and back. Physiol Rev. 2019;99(1):21–78.
8. Meyer JS, Itch Y, Okamoto S, et al. Circulatory and metabolic effects of glycerol infusion in patients with recent cerebral infarction. Circulation. 1975;51(4):701–12.
9. Rapoport SI. Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cell Mol Neurobiol. 2000;20(2):217–30.
10. Mondello S, Sorinola A, Cezi E, et al. Blood-based protein biomarkers for the management of traumatic brain injuries in adults presenting to emergency departments with mild brain injury: A living systematic review and meta-analysis. J Neurotrauma. 2021;38(8):1086–106.
11. Olivcrona M, Rodling-Wahlstrom M, Naredi S, Koskinen L.O. S-100B and neuron specific enolase are poor outcome predictors in severe traumatic brain injury treated by an intracranial pressure targeted therapy. J Neurol Neurosurg Psychiatry. 2009;80(11):1241–7.
12. Gao J, Zheng Z. Development of prognostic models for patients with traumatic brain injury: a systematic review. Int J Clin Exp Med. 2015;8(11):19881–5.
13. Grande PO. Critical evaluation of the Lund concept for treatment of severe traumatic head injury, 25 years after its introduction. Front Neurol. 2017;8:315.
14. Koskinen LO, Olivecrona M, Grande PO. Severe traumatic brain injury management and clinical outcome using the Lund concept. Neuroscience. 2014;283:245–55.

15. Olivecrona M, Rodling-Wahlstrom M, Naredi S, Koskinen LO. Prostacyclin treatment in severe traumatic brain injury: a microdialysis and outcome study. J Neurotrauma. 2009;26(8):1251–62.

16. Olivecrona Z, Bobinski L, Koskinen LO. Association of ICP, CPP, CT findings and S-100B and NSE in severe traumatic head injury. Prognostic value of the biomarkers. Brain Inj. 2015;29(4):446–54.

17. Bobinski L, Olivecrona M, Koskinen LO. Dynamics of brain tissue changes induced by traumatic brain injury assessed with the Marshall, Morris-Marshall, and the Rotterdam classifications and its impact on outcome in a prostacyclin placebo-controlled study. Acta Neurochir (Wien). 2012;154(6):1069–79.

18. Maas AI, Hukkelhoven CW, Marshall LF, Steyerberg EW. Prediction of outcome in traumatic brain injury with computed tomographic characteristics: a comparison between the computed tomographic classification and combinations of computed tomographic predictors. Neurosurgery. 2005;57(6):1173–82 (discussion -82).

19. Wilson JT, Pettigrew LE, Teasdale GM. Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. J Neurotrauma. 1998;15(8):573–85.

20. Jansson PA, Larsson A, Smith U, Linnroth P. Glycerol production in subcutaneous adipose tissue in lean and obese humans. J Clin Invest. 1992;89(5):1610–7.

21. Koskinen LO, Eklund A, Sundstrom N, Olivecrona M. Prostacyclin influences the pressure reactivity in patients with severe traumatic brain injury treated with an ICP-targeted therapy. Neurocrit Care. 2015;22(1):26–33.

22. Koskinen LD, Sundstrom N, Hagglund L, Eklund A, Olivecrona M. Prostacyclin affects the relation between brain interstitial glycerol and cerebrovascular pressure reactivity in severe traumatic brain injury. Neurocrit Care. 2019;31(3):494–500.

23. Berger C, Sakowitz OW, Kiening KL, Schwab S. Neurochemical monitoring of glycerol therapy in patients with ischemic brain edema. Stroke. 2005;36(2):e4-6.